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Abstract
Background: BRCA1/2-deficient ovarian carcinomas are recognized as target for Poly (ADP-ribose) polymerase
(PARP) inhibitors. BRCA1 and BRCA2 proteins are involved in homologous recombination repair of double-strand
DNA breaks. The relevance of other homologous recombination repair proteins, e.g. MRE11, RAD50, NBS1 (MRN
complex) in ovarian carcinomas is unclear. The objective of this study was to investigate the prevalence of lack of
MRE11, RAD50, NBS1 protein detection in epithelial ovarian cancer (EOC).
Methods: A tissue microarray (TMA) with 134 EOC was immunohistochemically evaluated for MRE11, RAD50 and
NBS1. Data was analysed for associations with clinicopathological parameters, histological subtype, patient overall
survival and mismatch repair (MMR) protein status. Sensitivity towards the PARP inhibitor BMN673 was tested in
two ovarian cancer cell lines (TOV-21 and OVTOKO) using colony formation assays.
Results: Lack of MRN complex protein detection was seen in 41% (55/134) of EOC and was more frequent in
low-grade (57.6%; 19/33) than in high-grade EOC (18.8%; 36/101; n = 134; p = 0.04). There was an association with the
ovarian carcinoma subtype (60.3%; 35/58 lack of detection in type I versus 26.3%; 20/76 in type II; n = 134; p < 0.001) as
well as undetectable DNA mismatch repair proteins MLH1 and MSH2 (89.3%; 25/28; n = 131; p < 0.001). MRE11
knockdown led to moderately increased sensitivity towards the PARP inhibitor BMN673 in one ovarian carcinoma cell
line in vitro.
Conclusions: Frequent lack of MRE11, RAD50, NBS1 protein detection in type I human ovarian carcinomas is observed
in EOC and our data suggests further investigation regarding sensitivity to PARP-inhibition in tumours lacking MRE11
expression.
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Background
Epithelial ovarian cancer (EOC) represents about 30% of
gynaecological cancers and is the leading cause of gynae-
cological cancer death in the Western world [1]. Patients
with EOC often present in an advanced disease stage [2].
The current treatment strategy is surgery followed by
platinum-based chemotherapy [3]. Due to resistance to
chemotherapy and recurrence of the disease, long term
survival of ovarian carcinoma patients remains poor.
Histologically, EOC is a heterogeneous group including
low- and high-grade serous cancer, mucinous, endome-
trioid and clear cell cancer. Germline BRCA1 and BRCA2
mutations account for about 10–15% of ovarian cancers
and are mainly found in high-grade serous and endome-
trioid ovarian carcinomas [4, 5]. BRCA1 and BRCA2 are
critical proteins in the process of homologous recombin-
ation repair (HR) of double-strand DNA breaks. In
addition to BRCA1 and BRCA2, many other proteins are
involved in the HR repair process of double-strand DNA
breaks and are implicated in hereditary breast and ovarian
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cancer susceptibility. Such genes include ATM, CHEK2,
BARD1, BRIP1, MRE11, RAD50, NBS1, RAD51C, RAD51D
and PALB2 [6]. In the initial stages of HR, a double-strand
DNA break is recognized by ATM and ATR, kinases that
phosphorylate downstream targets including p53 and
BRCA1. BRCA1 acts as a scaffold that organizes the
remaining proteins to the site of repair. In a second
phase of HR repair of double-strand DNA breaks, the
MRN complex, which consists of MRE11, RAD50 and
NBS1, resects the DNA to form 3″ overhangs. This is
followed by loading of RAD51 onto RPA-coated DNA
under the influence of BRCA2 [7–9].
The MRN complex can be inactivated or impaired by
mutations or epigenetic silencing occurring in one of its
three components. Homozygous MRE11 and NBS1 germ-
line mutations that cause a lethal phenotype in mice are
rarely encountered in humans and lead to an Ataxia
telangiectasia-like disorder (ATLD) and Nijmegen break-
age syndrome (NBS), respectively. Heterozygous germline
mutations of MRN complex genes may be associated with
breast and ovarian cancer susceptibility [10–13].
In recent years, HR repair of double-strand DNA breaks
has become a target for cancer therapy because BRCA1/2-
deficient cancers are recognized as a target for a class of
drugs known as PARP (poly (ADP-ribose) polymerase) in-
hibitors [14, 15]. PARP inhibitors work through direct
blocking of PARP enzymatic activity. PARP represents a
family of enzymes involved in base excision repair (BER),
a key pathway in the repair of single-strand DNA breaks.
Three excision repair pathways exist to repair single-
stranded DNA damage: Nucleotide excision repair (NER),
base excision repair (BER) and DNA mismatch repair
(MMR). Loss of DNA MMR proteins is seen in hereditary
non-polyposis colorectal cancer (HNPCC), but also in
ovarian carcinomas [7, 8, 16].
In the situation of PARP inhibition, single-strand DNA
breaks are converted into double-strand DNA breaks
through collapse of the replication fork. In BRCA-deficient
tumors, homologous recombination repair is not func-
tional. Therefore, the deficiency of both, HR repair of
double-strand DNA breaks and single-strand DNA
damage repair due to PARP inhibition leads to death of
tumor cells. The term synthetic lethality means that de-
ficiency of PARP or BRCA alone has no impact, but a
deficiency in both leads to a lethal effect in tumor cells
because the tumor cells are directed towards error-prone
repair and consecutive cell death [6].
In the last years, PARP inhibitors have shown promising
results among BRCA1/2 mutation carriers, among them
several completed trials for PARP inhibition in BRCA1
and BRCA2-mutated patients with EOC [14, 17, 18]. A
completed study in patients with relapsed high-grade
serous ovarian cancer showed improved progression
free survival among patients with platinum-sensitive
relapsed tumors, but no overall survival improvement
[19, 20].
In sporadic tumors, genes in DNA repair may also be al-
tered due to somatic mutations or epigenetic alterations.
In high-grade serous EOC, up to 50% harbor disruption of
HR by mutations or epigenetic silencing of BRCA1/2,
RAD51 and others [21] and up to 29% of EOC harbor
defects of MMR [22, 23]. The Cancer Genome Atlas
(TCGA) suggests that deficiency of either BRCA1 or
BRCA2 occurs through somatic mutation (3% BRCA1 or
BRCA2) or through epigenetic silencing of BRCA1 (11%)
in sporadic EOC. Other genetic changes affecting HR
repair include amplification of EMSY (8%), deletion/
mutation of PTEN (7%), hypermethylation of RAD51C
(3%), mutation of ATM or ATR (2%) or mutation of other
HR genes (5%). These tumors have the phenotype of
“BRCAness” and are predicted to act like BRCA-deficient
tumors despite wild-type germline BRCA1 and BRCA2
genes. Such BRCA-deficient ovarian cancers show im-
proved survival, due to a better response to platinum
chemotherapy [6].
In vitro experiments have demonstrated that deficiency
in HR by mutations in MRE11-RAD50-NBS1 (MRN)
complex may sensitize cancer cells to treatment with
PARP inhibitors [24–26] and might therefore serve as a
predictive biomarker of PARP inhibitor therapy. There is
some growing body of evidence that patients with other
mutations than BRCA1/2 may also benefit from PARP
inhibitors [15, 27–29].
So far, the expression pattern of the MRN complex in
gynaecological carcinomas is not well elucidated. Due to
the key role of the MRN complex in HR of double-strand
DNA breaks, the aim of our study was to evaluate the
prevalence of absent protein staining of the MRN complex
(MRE11, RAD50 and NBS1) in EOC.
Methods
Tissue microarray
Tissue microarray (TMA) with formalin-fixed and paraffin
embedded ovarian carcinomas was previously constructed
[30]. The study was approved by the local scientific ethics
committee (KEK-ZH-Nr: StV 27–2009) and the need for
individual consent has been waived by the ethics com-
mittee. 144 cancer samples of the archive of the Insti-
tute of Surgical Pathology, University Hospital Zurich
(Switzerland) were included in this study. Clinical and
pathological characteristics were taken from the clinical
databases and pathology records. Routine hematoxylin
and eosin sections were performed for histopathological
evaluation. The stage of tumors was assessed according
to the International Federation of Gynaecology and
Obstetrics (FIGO) and TNM staging system. Histological
subtype and tumor grade was defined according to the
WHO classification 2014 [31]. Low-grade serous
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carcinomas were excluded due to low sample number.
The histological grade was classified as low-grade (in-
cluding well to moderately differentiated endometrioid
and mucinous carcinomas) and high-grade (combining
high-grade serous, clear cell and poorly differentiated
endometrioid cancer). In addition, we classified all EOC
according to the Kurman model with two types of pro-
gression pathways as type I ovarian carcinomas (low-grade
serous cancer, mucinous, endometrioid and clear cell can-
cer) and type II ovarian carcinomas (especially high-grade
serous cancer) [32]. Follow-up data is known from all
patients. The mean follow-up time was 56.6 months
(range 0.13–201.2 months). Data on adjuvant chemo-
therapy were known for all patients. Adjuvant chemo-
therapy was administered in 102 women and was
mainly platinum based (68%). The remaining 42 pa-
tients (29.2%) did not receive any chemotherapy after
surgery. Resistance to chemotherapy is defined as dis-
ease progression or recurrence within 6 months after
end of therapy / within a 6 month therapy-free inter-
val. Sensitive status was defined as a therapy-free inter-
val of at least 6 months without evidence of tumor
progression or recurrence. In our cohort, 50 (34.7%)
cases were classified as sensitive (relapse >6 months)
and 32 (22.2%) as resistant (relapse <6 months). In 20
(13.9%) cases the response status could not be
determined.
Baseline characteristics of patients with ovarian cancer
are summarized in Table 1.
Immunohistochemistry
After antigen retrieval, the slides were incubated with
the following antibodies: MRE11 (clone 31H4, cell signal-
ling, no.4847, 1:500), RAD50 (13B3/2C6, Abcam limited,
no. ab89, 1:500), NBS1-p95 (cell signalling, no. 3002,
1:50). After incubation for 1 hour at room temperature,
the staining of MRE11, RAD50 and NBS1 was further
conducted with the Ventana Benchmark automated sys-
tem (Ventana Medical Systems, USA) using Ventana
reagents as well as the UltraMap™ DAB detection kit as
described previously [24]. Analysis of all stainings was
independently performed by two pathologists (SB, AN).
Nuclear immunoreactivity of MRE11, RAD50 and
NBS1 was scored as: negative (0), weak (1), moderate
(2) and strong (3). Stromal cells showing nuclear stain-
ing were used as a positive control.
The antibodies against the mismatch repair proteins
MLH1 (G168-15, PharMingen, Becton Dickinson, 1:100)
and MSH2 (25D12, Novocastra Lab. Ltd, 1:100) were
incubated for 30 min and the staining procedure was
carried out with the automated Leica BOND system using
the Bond Polymer Refine Detection Kit (Leica Biosystems)
as described previously [24]. The protein detection of the
mismatch repair genes was considered positive when nu-
clear staining was evident. Stromal and inflammatory cells
showing nuclear staining served as a positive control.
Cancer cell lines and growth conditions
The ovarian clear cell cancer (OCCC) cell lines TOV-21
and OVTOKO were grown in RPMI supplemented with
10% (v/v) fetal bovine serum and 1% (v/v) antibiotic-
antimycotic additive and incubated at 37 °C in a humidi-
fied atmosphere at 5% CO2. The serous ovarian cancer
cell line OV-90 was purchased at ATCC and grown in a
1:1 mixture of MCDB 105 medium containing a final
concentration of 1.5 g/L sodium bicarbonate and Medium
199 containing a final concentration of 2.2 g/L sodium
bicarbonate supplemented with 15% (v/v) fetal bovine
serum and 1% (v/v) antibiotic-antimycotic additive and
incubated at 37 °C in a humidified atmosphere at 5%
CO2. All cell culture components were purchased from
Gibco (LifeTechnologies).
siRNA and transfections
MRE11 knockdowns were performed simultaneously with
a pool of three different siRNA sequences (Microsynth,
Switzerland) using RNAimax (Gibco by LifeTechnologies)
according to the manufacturer’s instruction, each per-
formed as two independent experiments. The target se-
quences (sense) were: GCUAAUGACUCUGAUGAUATT,
GAGCAUAACUCCAUAAGUATT and GAUGCCAUUG
AGGAAUUAGTT [24]. The controls were transfected
with siRNA against luciferase (sense): CGUACGCGGA
AUACUUCGATT. Cells were seeded 24 h after siRNA
Table 1 Clinicopathological characteristics of ovarian
carcinomas (n = 144)
Variable n (%)
Age at diagnosis (n = 144)
≤ 60 years 67 (46.5)
> 60 years 77 (53.5)
FIGO stage (n = 137)
Early (I & II) 44 (32.1)
Late (III & IV) 93 (67.9)
Histological subtype (n = 144)
High-grade serous 73 (50.7)
Mucinous 15 (10.4)
Clear cell 26 (18.1)
Endometrioid 30 (20.8)
Grade (n = 144)
Low-grade 36 (25)
High-grade 108 (75)
Intraoperative residual tumor (n = 98)
< 1 cm 27 (27.6)
> 1 cm 71 (72.4)
Brandt et al. BMC Cancer  (2017) 17:44 Page 3 of 9
transfection and the treatment with the PARP inhibitor
BMN673 was initiated after 48 h [23].
Colony formation assays
The PARP inhibitor BMN673 was a gift from Biomarin
Pharmaceuticals, USA. Survival assays were carried out
as previously described [33, 34]. In brief, the previously
transfected cells were seeded in six-well plates in tripli-
cates at a concentration of 1000 cells per well. The
PARP inhibitor treatment was started after 24 h and
cells were continuously exposed to the PARP inhibitor
(10–11 to 10–6 M) and the medium was replaced every
3 to 5 days. The controls were treated with the vehicle
substance (DMSO). Cells cultures were grown until the
controls reached 80–90% confluence after 10 to 15 days
and then fixated with TCA 10%. After fixation, cell cul-
tures were stained with sulforhodamine B (SRB) (Sigma)
and a colorimetric assay was performed as described
previously [33].
Mutation analysis
The EOC cohort was previously characterized for KRAS
and TP53 gene mutations [35]. We analyzed KRAS exon
2 and 3 and TP53 exon 5–8 by pyrosequencing using
the GS Junior 454 platform.
Immunoblotting
Protein extraction was performed with a SDS lysis buffer.
The primary antibodies used for western blotting against
MRE11 (D151 (sheep), gift from Steve Jackson, Cambridge)
and beta-actin (mouse monoclonal antibody, Sigma). The
incubation was followed by an HRP-conjugated second-
ary antibody (anti-sheep HRP from Santa-Cruz and
anti-mouse HRP from Sigma), then followed by chemi-
luminescent detection (FemtoGlow Western, Michigan
Diagnostics, Cat # FWPS02-500). Images were acquired
electronically using a Fusion FX® (Vilber Lourmat,
Marne-la-Vallée, France) detecting system.
Statistical analysis
The statistical evaluation was performed with the SPSS
software Version 21.0 (SPSS Inc., Chicago, IL, USA).
The scoring data of MRE11, RAD50 and NBS1 were di-
chotomized into “negative” (no detection) and “positive”
(weak to strong detection). The statistical significance of
the association between these markers, the mismatch
repair protein detection as well as clinicopathological
parameters was assessed by Chi2 test and Fisher’s exact
test. In addition, Spearman’s correlation was used to
evaluate an association between MRE11, RAD50, NBS1
and mismatch repair proteins. The probability of over-
all survival as a function of time was determined by the
Kaplan-Meier method. Differences in survival curves
were compared by the log rank test. Sensitivity curves
were calculated in GraphPad Prism Version 6 (GraphPad
Software Inc., La Jolla, USA) and statistical differences be-
tween IC50 values were assessed using F-tests. The plotted
values represent the mean surviving fraction and the error
bars represent the standard error of mean (SEM) for two
independent knockdown experiments, with each experi-
ment perfomed in triplicates. P-values < 0.05 were consid-
ered as significant.
Results
MRN complex detection and clinicopathological parameters
Immunohistochemical analysis of MRE11, RAD50 and
NBS1 was successful in a maximum of 134 carcinomas.
Staining results for some TMA spots were not obtained
due to loss of tumor tissue during technical processing.
MRE11, RAD50 and NBS1 immunohistochemical reac-
tions showed only nuclear staining. The immunohisto-
chemical data are summarized in Table 2. Representative
images are shown in Fig. 1. Non-neoplastic stromal cells
showed sustained staining of all three markers. For further
statistical analysis, only completely absent staining (score
0) was considered as negative and any detectable staining
(weak to strong) was considered positive.
Statistically, we found a significant positive association
between MRE11 and RAD50 as well as NBS1 detection
(Table 3, p < 0.0001, Fisher’s Exact test). Further, a signifi-
cant positive association was found between RAD50 and
NBS1 (p < 0.0001, Fisher’s Exact test). Due to this associ-
ation, we defined a combined loss of MRN complex pro-
teins as loss of either of the proteins MRE11, RAD50 or
NBS1.
We evaluated the association of the MRN complex
(combined detection of all three proteins) with clinico-
pathological factors. Lack of MRN complex detection
was significantly associated with histological subtype and
differentiation grade. According to the Kurman progression
Table 2 Immunohistochemical detection of MRN complex
proteins
Immunohistochemical detection n (%)
MRE11 (n = 136)
Negative 49 (36.0)
Positive 87 (64.0)
RAD50 (n = 136)
Negative 14 (10.3)
Positive 122 (89.7)
NBS1 (n = 135)
Negative 45 (33.3)
Positive 90 (66.7)
MRN complex (n = 134)
Negative 55 (41.0)
Positive 79 (59.0)
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pathway model [32], lack of MRN protein detection oc-
curred significantly more frequently in type I tumors (p <
0.001, Table 4).
MRE11, RAD50 and NBS1 Detection and Mismatch Repair
Protein Detection
We investigated mismatch repair protein expression by
immunohistochemistry in a maximum of 133 ovarian
carcinomas. Any lack of detection of one of the proteins
MSH2 or MLH1 was integrated in a MMR deficiency
state. MMR deficiency was observed in 21% of all EOC.
All three MSH2 negative cases were also negative for
MLH1.
MRE11, RAD50 and NBS1 were significantly associated
with mismatch repair protein detection (p < 0.05, Fisher’s
Exact test). The correlation among all proteins was
confirmed in a bivariate (nonparametric) analysis (MRE11
and RAD50 (correlation coefficient 0.451; n = 135; p-
value <0.001); MRE11 and NBS1 (correlation coefficient
0.741; n = 135; p-value <0.001); RAD50 and NBS1 (correl-
ation coefficient 0.377; n = 134; p-value <0.001)), calculated
with Spearman’s rho.
MRN complex overall survival and response to
chemotherapy
In univariate Kaplan-Meier analysis, FIGO stage, histologic
subtype, grading and patient age were significant prognos-
tic factors for overall survival (log rank, p-value <0.05 for
each parameter). Detection of MRE11 (log rank, p = 0.28),
RAD50 (log rank, p = 0.32), NBS1 (log rank, p = 0.9),
MMR status (log rank, p = 0.79) was not associated with
Fig. 1 Immunohistochemical staining of MRE11 a & b, RAD50 (c & d)
and NBS1 (e & f) (20× magnification). a Only complete absence of
nuclear staining for MRE11 in tumor cells (⋆) was considered as
negative staining. Adjacent normal tissue served as positive internal
control (▶). Examples of undetectable RAD50 (c) and NBS1 (e) in
tumor cells. Any nuclear staining of MRE11 (b), RAD50 (d) or NBS1 (f)
was considered as positive
Table 3 Association of the MRN complex proteins
MRE11 negative n (%) MRE11 positive n (%) p-value
RAD50 (n = 135)
Negative 14 (10.4) 0 (0)
Positive 35 (25.9) 86 (63.7) <0.001a
NBS1 (n = 135)
Negative 39 (28.9) 6 (4.4)
Positive 10 (7.4) 80 (59.3) <0.001a
MMR (n = 133)
Negative 25 (18.8) 3 (2.3)
Positive 22 (16.5) 83 (62.4) <0.001a
aFisher’s Exact test
Table 4 Association of MRN complex with clinicopathological
factors and MMR status
Variable n MRN complex negative n (%) p-value
FIGO stage
Early (I & II) 40 20 (50) 0.017a
Late (III & IV) 88 32 (36.4)
Histologic subtype
High-grade serous 67 17 (25.4) 0.001b
Mucinous 14 9 (64.3)
Clear cell 25 16 (64.0)
Endometrioid 28 13 (46.4)
Grade
Low-grade 33 19 (57.6) 0.04a
High-grade 101 36 (35.6)
Kurman model’
Type I 58 35 (60.3) 0.0001a
Type II 76 20 (26.3)
MMR status
Negative 28 25 (89.3) <0.0001a
Positive 103 27 (26.2)
KRAS status
wt 114 43 (37.7) 0.082a
Mutation 14 9 (64.3)
TP53 status
wt 58 24 (41.4) 0.9a
Mutation 70 28 (40.0)
aFisher’s Exact test; bchi-square Pearson
Brandt et al. BMC Cancer  (2017) 17:44 Page 5 of 9
overall survival. NBS1 detection tended to be associated
with a platinum-sensitive status (p = 0.058, Fisher’s Exact
Test). MRE11 and RAD50 did not show any association
with response to chemotherapy.
Association of the MRN complex with KRAS and TP53
mutation status
Since KRAS and TP53 gene mutations are important in
ovarian carcinogenesis, we evaluated whether an associ-
ation can be found with mutation status, which was re-
cently described in our cohort [35]. Ovarian carcinomas
with KRAS mutation showed frequent lack of NBS1 detec-
tion (p = 0.013, Fisher’s exact test) and a trend for MRE11
negativity (p = 0.08, Fisher’s exact test). No association
with TP53 mutation status was observed (Table 4).
Knockdown of MRE11 sensitizes OCCC cells towards the
PARP inhibitor BMN673 in vitro
We assessed PARP inhibitor sensitivity in the MRE11-
depleted cells by colony formation in triplicates. The
efficiency of the siRNA knockdowns was verified by
western blots as described before [21]. Upon depletion
of MRE11, we observed a moderate decrease in cell viabil-
ity in the presence of the PARP inhibitor BMN673 (Fig. 2).
The IC50 values for BMN673 were 4.1 e–10 M in the
MRE11-depleted TOV21 and 9.3 e–10 M in the controls
(p = 0.0005). In OVTOKO IC50 was 5.4 e–9 M in the
MRE11-depleted cell line and 7.5 e–9 M in the controls
(p = 0.2).
Discussion
In this study, immunohistochemical analysis showed a
frequent lack of detection of the MRN complex (MRE11,
RAD50, NBS1) in EOC. With our immunohistochemical
approach, we provide evidence for lack of protein detec-
tion of RAD50 in 10% (14/136), NBS1 in 33% (45/135)
and MRE11 in 36% (49/136) of EOC. In a combined MRN
score, 44% (55/134) of all EOC have at least one undetect-
able protein of the three MRN proteins. Our finding is
consistent with results of a previous study that demon-
strated a reduced detection of MRE11, RAD50, and NBS1
in cancer tissue by immunohistochemistry as compared to
the control group of healthy ovaries and serous cystadeno-
mas [36]. Recently, we investigated these proteins in endo-
metrial cancer (EC) and observed a lack of detection in up
to 30% of the cases [9].
There are different mechanisms of MRN protein defi-
ciency. Mutations of genes of the MRN complex have
been described in other cancers, including colorectal and
endometrial cancer. For MRE11, mutations of the intronic
poly (T) sequence between exons 4 and 5 are frequent
events in MSI-positive colorectal and endometrial cancers
[37, 38]. However, in a recent next-generation sequencing
study by exome-wide analysis in ovarian cancer, the
prevalence of MRN gene mutations is uncommon.
MRE11 accounted for only 3% of somatic mutations of
HR genes and NBS1 only for 1% of germline mutations,
respectively [6]. Therefore, different mechanisms which
lead to undetectable MRN proteins might be suggested,
such as epigenetic silencing [39] and post-transcriptional
regulation by miRNA [40].
We observed an association between lack of MRN
detection and MMR deficiency, assessed by MLH1 and
MSH2 immunohistochemistry. MLH1 functions as a
nuclear-encoded protein in mitochondrial mismatch
repair, MSH2 functions in nuclear mismatch repair.
Germline mutations in MSH2 and MLH1 account for
the majority of HNPCC families implicating mismatch
repair as etiology [41]. We have previously shown that
nuclear immunoreactivity for MLH1, MSH2 or MSH6
proteins is retained in all microsatellite stable ovarian
carcinomas [22]. 65% of microsatellite instable ovarian
carcinomas displayed some detectable MLH1, MSH2
and MSH6, but a complete lack of MLH1, MSH2 or
MSH6 detection was only seen in carcinomas with
microsatellite instability [22, 42]. Therefore, our data
indicate that lack of MRN detection can be associated
with MMR deficiency in EOC. This is consistent with
recent studies, showing that somatic mutations in MRE11
are frequently detected in MSI-positive colorectal and
endometrial cancers [6, 37, 38, 43]. Previously, we have
observed that lack of MRN protein detection was also as-
sociated with undetectable MMR proteins in endometrial
cancer [24]. This suggests that the components of the
MRN complex might be a common target of MSI and
might contribute to tumor progression.
In vitro experiments demonstrate that deficiency in HR
by mutations in the MRE11-RAD50-NBS1 (MRN) com-
plex may sensitize cancer cells to treatment with PARP in-
hibitors [26, 29, 44, 45]. We observed an increased
sensitivity towards the PARP inhibitor BMN673 in the
OCCC cell line TOV21 after knockdown of MRE11. A
similar tendency was observed in the second OCCC cell
line OVTOKO. The OCCC cell lines were chosen because
of the higher rate of undetectable MRN proteins among
the Type I ovarian cancer group in our TMA. The in-
crease in PARP inhibitor sensitivity after MRE11 knock-
down is in line with previous observations made in
endometrial cancer cell lines [24]. However, the effect
was less pronounced in the OCCC cell lines which may
be caused by factors like reduced transfection efficiency
in these cell lines.
Our data suggest that loss of MRE11 in ovarian and
endometrial cancer may predict sensitivity to PARP inhibi-
tor in vitro and supports further investigation on MRE11
as a predictive biomarker for PARP inhibitor treatment
[24]. However, the deficiency of several proteins other than
BRCA1/2 or the MRN complex involved in HR, such as
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RAD51, RAD54, DSS1, RPA1, ATR, ATM, CHK1, CHK2,
FANCD2, FANCA or FANCC might also be sensitive to
treatment with PARP inhibitors [6, 46].
In this study, MRN complex detection was not associ-
ated with response to chemotherapy or overall survival,
which is consistent with previous studies in EOC [36] or
endometrial cancer [24]. Although, loss of MRN complex
is associated with impaired HR DNA repair [47], which
renders cancer cells exquisitely sensitive to platinum-salts.
This was recently shown in a large series of 390 ovarian
cancer samples, where defects in HR were predictive for
overall survival and primary platinum sensitivity [6]. The
impact of MMR deficiency on chemotherapy resistance in
EOC is controversial and investigated to a lesser extent
[23]. The complex role and interaction of the MRN com-
plex and MMR status has to be further evaluated.
Our data suggest that lack of MRN complex detection
is more frequent in nonserous histologies (type I EOC)
than in high-grade serous EOC [32]. Undetectable MRN
protein was only weakly associated with low differenti-
ation grade (p < 0.05). We classified the histological
grade as low-grade (including well to moderately differ-
entiated endometrioid and mucinous carcinomas) and
high-grade (combining high-grade serous, clear cell and
poorly differentiated endometrioid cancer). Importantly,
undetectable MRN complex showed stronger association
with the Kurman model of two progression pathways:
Type I low-grade ovarian carcinomas (low-grade serous
cancer, mucinous, endometrioid and clear cell cancer),
which are characterized by mutations in genes like KRAS,
BRAF, ERBB2, PTEN, PI3KCA, CTNNB1, ARID1A and
PPP2R1A, in the absence of TP53 mutations. These type I
EOC more often showed an undetectable MRN complex
than the aggressive type II high-grade ovarian carcinomas
(especially high-grade serous cancer) with a high fre-
quency of TP53 mutations [32]. Type II EOC typically
occurs in patients with germline BRCA1 and BRCA2
mutations, which are treated with PARP inhibitors. Our
data suggest that patients with type I EOC may also
benefit from PARP inhibitors.
Finally, we searched for an association between gene
mutations of TP53 and KRAS and the protein detection
of the MRN complex. Lack of NBS1 protein detection
was associated with KRAS mutation, presumably due to
the strong association between type I EOC and lack of
MRN protein detection. In a previous study, a relation
of NBS1 to the RAS/RAF/MER/ERK cascade and its in-
fluence in cell proliferation was shown [34]. Thus, NBS1
Fig. 2 Sensitivity of the OCCC cell lines TOV-21, OVTOKO and ovarian serous cancer cell line OV-90 towards the PARP inhibitor BMN673 after knockdown
of MRE11. Treatment with the PARP inhibitor BMN673 led to moderately decreased cell viability in (a) MRE11-depleted TOV21 (p = 0.0005) but not in (b)
MRE11-depleted OVTOKO (p = 0.2) and OV-90 (c) (p = 0.8) compared to the respective controls. P-values indicate the differences in the IC50
values as calculated with an F-test using GraphPad Prism Version 6. The plotted values represent the mean surviving fraction and the error
bars represent the standard error of mean (SEM). Western blot analysis (d) showed a decrease but not a loss of MRE11 expression in all the
three cell lines after siRNA treatment and all the knockdown experiments were performed two times independently each. All the experiments
were performed in triplicate 6-well plates
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is not only involved in DNA repair but also in other cel-
lular processes such as signalling and proliferation. It
was further reported that p53 mutants interact with the
MRN complex [48]. However, in our cohort we did not
observe an association between TP53 mutated ovarian
carcinomas and MRN complex detection. This can be
explained by the weak association of MRN deficiency
with type II EOC.
Conclusion
In conclusion, lack of protein detection of the MRN
complex occurs more frequently in low-grade EOC and
is associated with MMR deficiency. A potential role of
MRN as a biomarker for therapies targeting cancers with
BRCAness such as PARP inhibitors needs to be exam-
ined in clinical trials.
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